Skip to content

Psilocybin: all studies

Page 396 of 440: studies 3,951 to 3,960 of 4,392, newest first. Back to the psilocybin overview

Research

2 World War II Changes Everything

Rowman & Littlefield Publishers eBooks 2022 Patrick L. Schmidt

In Harvard’s Quixotic Pursuit of a New Science, Patrick L. Schmidt tells the little-known story of how some of the most renowned social scientists of the twentieth century struggled to elevate their emerging disciplines of cultural anthropology, sociology, and social and clinical psychology. Scorned and marginalized in their respective departments in the 1930s for pursuing the controversial...

DOI: 10.5771/9781538168301-29 (opens in new tab) Jungian analytical psychology

Psicoterapia assistida por psilocibina no tratamento da depressão

2022 Gabriela Zorzi Marcello Marcello, Tânia Marcourakis

A depressão é uma doença que acomete cerca de 3,4% da população mundial e para a qual, até hoje, existem diversas barreiras para que se possa alcançar a cura. Os tratamentos atuais baseiam-se em medicação antidepressiva, sendo de primeira escolha, na maior parte dos casos, a classe dos inibidores seletivos da recaptação de serotonina (ISRS). No cenário de utilização da farmacoterapia com...

DOI: 10.11606/003103379 (opens in new tab) Full text (opens in new tab) Medline Perspective graphical Psychic Clinical practice +1

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Psychopharmacology 2022 Nina Schimmers, Joost J. Breeksema, Sanne Y Smith-Apeldoorn et al.

Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option. Systematically review studies on psychedelic treatment with and without psychotherapy for...

The age of psychedelics

Journal of Psychopharmacology 2022 A. H. Young 3 citations

The 21st century has seen a dramatic flow and ebb in the fortunes of clinical psychopharmacology particularly with regard to antidepressants. For about 20 years, perhaps from about 1985 onwards, the tide flowed in with many ‘new’ drugs being made available to clinicians. In mood and psychotic disorders, these were essentially incremental advances from old drugs such as amitriptyline and...

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer

Drug Science, Policy and Law 2022 Rayyan Zafar, Dustin Sulak, Jaime Brambila et al. 3 citations

A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initially of a titrated high-dose...

Harvard's Quixotic Pursuit of a New Science

Rowman & Littlefield Publishers eBooks 2022 Patrick L. Schmidt 7 citations

In Harvard’s Quixotic Pursuit of a New Science, Patrick L. Schmidt tells the little-known story of how some of the most renowned social scientists of the twentieth century struggled to elevate their emerging disciplines of cultural anthropology, sociology, and social and clinical psychology. Scorned and marginalized in their respective departments in the 1930s for pursuing the controversial...

A comparative study of the harms of nitrous oxide and poppers using the MCDA approach

Drug Science, Policy and Law 2022 Plinio Ferreira, Adam Winstock, Anne Katrin Schlag et al. 9 citations

The recent surge in recreational (non-medical) use of nitrous oxide (N 2 O, also known as ‘laughing gas’) often by inhaling it from balloons, has attracted the attention of some politicians with calls to control its possession under the United Kingdom (UK) Misuse of Drugs Act 1971 (currently selling, but not possession, for recreational use is controlled under the Psychoactive Substances Act...

DOI: 10.1177/20503245221127301 (opens in new tab) Recreational drug Harm reduction

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review

Chronic Stress 2022 Sarah Kuburi, Anne-Marie Di Passa, Vanessa K Tassone et al. 14 citations

Preliminary evidence supports the use of psychedelics for major depressive disorder (MDD). However, less attention has been given to the neural mechanisms behind their effects. We conducted a systematic review examining the neuroimaging correlates of antidepressant response following psychedelic interventions for MDD. Through MEDLINE, Embase, and APA PsycINFO, 187 records were identified and 42...

DOI: 10.1177/24705470221115342 (opens in new tab) Neuroimaging Clinical psychology

"O USO TERAPÊUTICO INDEPENDENTE DE MICRODOSAGEM DE PSILOCIBINA SOB PROTOCOLO FADIMAN : UM DIÁRIO DO AUTO-CONHECIMENTO"

Anais do 14º Congresso Brasileiro de Naturologia: Paradigmas contemporâneos da saúde mental e as novas perspectivas da medicina botânica 2022 Priscila Franco Saraiva Monteiro

A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero Psilocybe, como P. azurescens, P. semilanceata e P. c

DOI: 10.29327/1147850.14-1 (opens in new tab) Sub-perceptual dosing Psilocybin microdosing Low-dose psilocybin Psychedelic microdosing +14

Dosing Psychedelics and MDMA.

Current Topics in Behavioral Neurosciences 2022 Matthias E. Liechti, Friederike Holze 35 citations

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others....

DOI: 10.1007/7854_2021_270 (opens in new tab) Full text (opens in new tab) Microdosing Ego-dissolution dose Good effect dose Personalized medicine +1